The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.
aggressive non-Hodgkin lymphoma
children and adolescents
non-Hodgkin lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
26
01
2022
revised:
10
03
2022
accepted:
14
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.
Identifiants
pubmed: 35326719
pii: cancers14061569
doi: 10.3390/cancers14061569
pmc: PMC8945992
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Med Chem. 2016 Nov 10;59(21):9928-9941
pubmed: 27739677
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798
pubmed: 31648953
Cancer Cell. 2013 May 13;23(5):677-92
pubmed: 23680150
Front Cell Dev Biol. 2020 Sep 03;8:576391
pubmed: 33015069
Clin Epigenetics. 2019 Dec 10;11(1):188
pubmed: 31823832
Hematol Oncol Stem Cell Ther. 2017 Sep;10(3):126-134
pubmed: 28390216
Nat Immunol. 2003 Feb;4(2):124-31
pubmed: 12496962
Anticancer Drugs. 2021 Jan 1;32(1):34-43
pubmed: 33079733
Ther Adv Hematol. 2015 Oct;6(5):242-52
pubmed: 26425337
Cancer Discov. 2015 May;5(5):475-87
pubmed: 25895919
Ochsner J. 2018 Winter;18(4):370-376
pubmed: 30559623
Biochem Pharmacol. 2019 Apr;162:250-261
pubmed: 30668936
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Vaccines (Basel). 2020 Nov 27;8(4):
pubmed: 33260966
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33361336
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
N Engl J Med. 2020 Jun 4;382(23):2207-2219
pubmed: 32492302
Leuk Lymphoma. 2018 Mar;59(3):670-678
pubmed: 28768446
Leukemia. 2020 Aug;34(8):2271-2275
pubmed: 32071430
Blood. 2016 Jan 28;127(4):411-9
pubmed: 26542378
Hemasphere. 2020 Jun 08;4(3):e398
pubmed: 32647802
Cancers (Basel). 2018 Feb 28;10(3):
pubmed: 29495603
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):589-597
pubmed: 27913533
Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302
pubmed: 22440390
Expert Opin Pharmacother. 2014 Nov;15(16):2443-59
pubmed: 25263936
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
Lancet. 2018 Feb 17;391(10121):659-667
pubmed: 29241979
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
Anticancer Res. 2014 Oct;34(10):5287-94
pubmed: 25275021
J Pers Med. 2021 Apr 29;11(5):
pubmed: 33946635
Mol Cancer. 2010 Nov 25;9:305
pubmed: 21108789
Cancer Sci. 2017 Oct;108(10):2069-2078
pubmed: 28741798
Haematologica. 2019 Sep;104(9):1822-1829
pubmed: 30733272
Eur J Cancer. 2022 Mar;163:140-151
pubmed: 35074650
Drugs R D. 2019 Jun;19(2):73-92
pubmed: 30993606
Chem Biol. 2013 Nov 21;20(11):1329-39
pubmed: 24183969
J Clin Oncol. 2009 Aug 10;27(23):3822-9
pubmed: 19581539
Br J Haematol. 2016 May;173(4):617-24
pubmed: 27009921
Mol Carcinog. 2019 Jun;58(6):944-956
pubmed: 30693983
Cancer Discov. 2021 Jun;11(6):1440-1453
pubmed: 33593877
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
Clin Cancer Res. 2021 Sep 1;27(17):4690-4695
pubmed: 34083230
Leuk Lymphoma. 2021 Apr;62(4):810-818
pubmed: 33236943
Blood Adv. 2019 Aug 27;3(16):2491-2498
pubmed: 31451445
Signal Transduct Target Ther. 2020 Jul 29;5(1):134
pubmed: 32728035
Cancers (Basel). 2021 Nov 29;13(23):
pubmed: 34885113
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Lancet Oncol. 2020 Apr;21(4):541-550
pubmed: 32192573
Cells. 2022 Jan 02;11(1):
pubmed: 35011701
Acta Pharm Sin B. 2018 Jul;8(4):539-551
pubmed: 30109179
Cancer Chemother Pharmacol. 2020 Dec;86(6):829-840
pubmed: 33095287
Annu Rev Pharmacol Toxicol. 2005;45:495-528
pubmed: 15822187
Haematologica. 2017 Jun;102(6):1091-1098
pubmed: 28209658
Genes Dev. 2004 Aug 15;18(16):1926-45
pubmed: 15314020
J Cancer Res Clin Oncol. 2020 Jun;146(6):1575-1582
pubmed: 32222815
Nat Commun. 2015 Jul 16;6:7768
pubmed: 26178471
Theranostics. 2016 Jan 06;6(3):369-91
pubmed: 26909112
Cancers (Basel). 2020 Dec 18;12(12):
pubmed: 33353234
Leukemia. 2005 Dec;19(12):2313-23
pubmed: 16193090
Mutat Res. 2008 Dec 1;647(1-2):21-9
pubmed: 18723033
Oncogene. 2007 Aug 13;26(37):5310-8
pubmed: 17694074
Curr Hematol Malig Rep. 2018 Oct;13(5):369-382
pubmed: 30112706
J Hematol Oncol. 2017 Mar 15;10(1):69
pubmed: 28298231
Cancer J. 2019 Nov/Dec;25(6):386-393
pubmed: 31764119
Curr Oncol Rep. 2011 Oct;13(5):398-406
pubmed: 21755275
Lancet Oncol. 2021 Dec;22(12):1646-1648
pubmed: 34780708
J Hematol Oncol. 2021 Jun 5;14(1):88
pubmed: 34090506
Leuk Lymphoma. 2008;49 Suppl 1:59-66
pubmed: 18821434
Br J Haematol. 2015 Jul;170(1):118-22
pubmed: 25833390
Leuk Lymphoma. 2018 Jul;59(7):1574-1585
pubmed: 29473431
Br J Haematol. 2006 Aug;134(4):391-8
pubmed: 16882131
Hemasphere. 2021 Sep 23;5(10):e636
pubmed: 34589671
ESMO Open. 2021 Aug;6(4):100172
pubmed: 34242968
Br J Haematol. 2019 Jun;185(6):1055-1070
pubmed: 30613939
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Front Genet. 2019 Oct 16;10:986
pubmed: 31681423
Clin Cancer Res. 2009 Jun 15;15(12):3958-69
pubmed: 19509172
Clin Pharmacokinet. 2019 Feb;58(2):157-168
pubmed: 29802543
Oncoimmunology. 2018 Oct 11;8(1):e1512455
pubmed: 30546948
Curr Opin Genet Dev. 2016 Feb;36:50-8
pubmed: 27151431
Pediatr Hematol Oncol. 2020 Sep;37(6):465-474
pubmed: 32338562
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11753-9
pubmed: 26617922
Blood. 2014 May 22;123(21):3286-95
pubmed: 24659631
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252
pubmed: 28882879
Br J Haematol. 2019 Jun;185(6):1021-1042
pubmed: 30729513
Lancet Haematol. 2018 Oct;5(10):e450-e461
pubmed: 30290902
J Natl Compr Canc Netw. 2020 Aug;18(8):1125-1134
pubmed: 32755987
Cancers (Basel). 2018 Mar 30;10(4):
pubmed: 29601554
Molecules. 2021 Sep 27;26(19):
pubmed: 34641391
Int J Cancer. 2021 Dec 15;149(12):2075-2082
pubmed: 34398971
ACS Chem Biol. 2013;8(6):1324-34
pubmed: 23614352
Lancet Oncol. 2020 Jan;21(1):134-144
pubmed: 31780255
Blood Cancer J. 2015 Oct 16;5:e361
pubmed: 26473533
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
Clin Cancer Res. 2010 Feb 1;16(3):888-97
pubmed: 20086002
Blood. 2009 Apr 30;113(18):4403-13
pubmed: 19008458
Cancer Res. 1999 Jun 1;59(11):2615-22
pubmed: 10363983
Br J Haematol. 2002 May;117(2):322-32
pubmed: 11972514
N Engl J Med. 1987 Jan 8;316(2):79-84
pubmed: 3537802
Blood. 2020 Jan 16;135(3):159-166
pubmed: 31738819
Blood. 2019 Jul 4;134(1):22-29
pubmed: 30952672
Eur J Haematol. 2014 Dec;93(6):455-68
pubmed: 24766435
Blood. 2020 Jan 23;135(4):274-286
pubmed: 31738823
Leuk Lymphoma. 2019 Nov;60(11):2622-2634
pubmed: 31018735
Front Immunol. 2021 Jun 23;12:681984
pubmed: 34248965
Br J Haematol. 2010 Feb;148(4):600-10
pubmed: 19895612
Leuk Res Rep. 2021 Oct 24;16:100275
pubmed: 34765437
Crit Rev Oncol Hematol. 2019 Apr;136:56-63
pubmed: 30878129
Xenobiotica. 2020 Jun;50(6):640-653
pubmed: 31596164
BMC Cancer. 2017 Jun 2;17(1):399
pubmed: 28578655
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1844-1855
pubmed: 32727723
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5
pubmed: 23236167
J Cancer Res Clin Oncol. 2021 Nov;147(11):3441-3445
pubmed: 33856526
J Biomed Sci. 2021 Apr 12;28(1):27
pubmed: 33840388
J Fungi (Basel). 2021 Mar 05;7(3):
pubmed: 33807678
Blood. 2021 Jul 1;137(26):3595-3603
pubmed: 33684925
Leukemia. 2021 Feb;35(2):312-332
pubmed: 33122850
Crit Rev Oncol Hematol. 2020 Aug;152:103010
pubmed: 32540781
Leuk Res. 2016 Mar;42:93-104
pubmed: 26818572
Drugs Context. 2021 Sep 21;10:
pubmed: 34603459
Drug Des Devel Ther. 2018 Jul 24;12:2293-2300
pubmed: 30087554
Leuk Lymphoma. 2019 Nov;60(11):2635-2645
pubmed: 30958073
Blood Adv. 2020 Nov 24;4(22):5652-5665
pubmed: 33211828
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):135-40
pubmed: 26629279
Cells. 2021 Sep 23;10(10):
pubmed: 34685497
Nat Rev Drug Discov. 2006 Feb;5(2):107-14
pubmed: 16518378
Ther Adv Hematol. 2017 Aug;8(8):223-234
pubmed: 28811872
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29193772
Int J Cancer. 2006 Aug 15;119(4):757-64
pubmed: 16550606
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
Am J Pathol. 2004 Jul;165(1):159-66
pubmed: 15215171
Mod Pathol. 2020 Mar;33(3):324-333
pubmed: 31383967
Leukemia. 2001 Oct;15(10):1582-8
pubmed: 11587216
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Biomolecules. 2020 Jul 21;10(7):
pubmed: 32708132
Blood Cancer J. 2017 Sep 8;7(9):e603
pubmed: 28885612
BMC Cancer. 2018 Feb 1;18(1):122
pubmed: 29390984
J Clin Oncol. 2011 Feb 20;29(6):690-7
pubmed: 21189393
Leukemia. 2011 Jan;25(1):153-60
pubmed: 21030984
Cell Signal. 2010 Aug;22(8):1175-84
pubmed: 20206686
J Hematol Oncol. 2019 Nov 21;12(1):118
pubmed: 31752930
Clin Pharmacokinet. 2020 Apr;59(4):463-474
pubmed: 31679130
J Clin Exp Hematop. 2017;57(3):120-142
pubmed: 29279550
Blood. 1997 Aug 1;90(3):1168-74
pubmed: 9242549
Curr Oncol. 2019 Apr;26(2):e233-e240
pubmed: 31043832
Blood. 2020 Oct 1;136(14):1657-1669
pubmed: 32573700
Cancer. 2015 Oct 1;121(19):3465-71
pubmed: 26079295